The psychedelic renaissance: the next trip for psychiatry?

@article{Kelly2019ThePR,
  title={The psychedelic renaissance: the next trip for psychiatry?},
  author={John R. Kelly and Anne Pimlott Baker and Muneef Babiker and Lisa Burke and C. Brennan and Veronica O’Keane},
  journal={Irish journal of psychological medicine},
  year={2019},
  pages={
          1-5
        }
}
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode… 

Psychedelic science in post-COVID-19 psychiatry

Preliminary evidence from the rapidly progressing field of psychedelic science shows psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder.

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Pre-clinical and clinical evidence of the acute and sustained therapeutic potential of psychedelic therapy in the context of a transdiagnostic dimensional systems framework is reviewed, focusing on the Research Domain Criteria (RDoC) as a template, to assist the field in moving toward a mechanistic understanding of how psychedelics work for patients.

Default Mode Network Modulation by Psychedelics: A Systematic Review.

Psychedelics are a unique class of drug which commonly produce vivid hallucinations as well as profound psychological and mystical experiences. A grouping of interconnected brain regions

Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test

The findings supported the EP model and suggest that a suitability test may be a useful tool when determining whether a prescription of psilocybin is an appropriate course of treatment.

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies

A subanalysis of the ten most cited articles in psychedelic research prior to 2010 and afterwards demonstrated a shift from research on risks of psychedelics, primarily those of MDMA, to research on therapeutic applications, predominantly those of psilocybin.

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

In this study, we describe the development and initial validation of two psychometric scales for measuring psychedelic integration. Psychedelic integration refers to the post-acute period of time

References

SHOWING 1-10 OF 48 REFERENCES

How do psychedelics work?

It is proposed that psychedelics initiate a cascade of neurobiological changes that manifest at multiple scales and ultimately culminate in the relaxation of high-level beliefs and the purpose of psychedelic therapy is to harness the opportunity afforded by this belief-relaxation to achieve a healthy revision of pathological beliefs.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Psychedelics and Mental Health: A Population Study

It was found that in several cases psychedelic use was associated with lower rate of mental health problems, and use of psychedelics was not found to be an independent risk factor formental health problems.

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.

Psychedelics and Psychotherapy in Canada: Humphry Osmond and Aldous Huxley

The decade of the 1950s is well known among historians of psychiatry for the unprecedented shift toward psychopharmacological solutions to mental health problems. More psychiatric medications were

Psychedelics and the essential importance of context

This article highlights the pharmacological mechanisms of classic psychedelics that it is believed render their effects exceptionally sensitive to context, and develops an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

The post-treatment brain changes are different to previously observed acute effects of psilocybin and other ‘psychedelics’ yet were related to clinical outcomes, and a ‘reset’ therapeutic mechanism is proposed.

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Psilocybin caused a significant decrease in the positive coupling between the mPFC and PCC, which strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector hubs, enabling a state of unconstrained cognition.

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.